Merck to Present Latest Cancer Research Advancements at ASCO 2024
First-in-human data for the potential first-in-class anti-CEACAM5 ADC with topoisomerase 1 inhibitor payload, M9140, in the treatment of metastatic colorectal cancer to be featured in an oral presentation. Phase I…
Lilly Invests $9B in Indiana Site to Boost Tirzepatide and Pipeline API Production
Eli Lilly and Company announced today a significant increase in investment for its Lebanon, Indiana, manufacturing site. The company has committed an additional $5.3 billion, bringing the total investment to…
Astellas and YASKAWA Partner to Forge a Cutting-Edge Cell Therapy Ecosystem Blending Pharmaceutical and Robotics Expertise
Today, Astellas announced the signing of a memorandum of understanding with YASKAWA Electric Corporation (YASKAWA), marking the beginning of discussions toward creating an innovative cell therapy ecosystem. This collaboration aims…
Nature Communications: CSL, Arcturus COVID-19 Vaccine Efficacy Data Published
CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) have announced the publication of groundbreaking findings in Nature Communications, revealing the results from a comprehensive phase 1/2/3a/3b study investigating the safety,…
Aetna Grants $400K for Roanoke, VA Residential Facility Helping Moms with Substance Use Disorder
Aetna Better Health of Virginia, a CVS Health® company, has pledged $400,000 to Restoration Housing to facilitate the acquisition of a property in Roanoke, Virginia. This property will be utilized…
Empowering Schizophrenia Community: Live Your PosSCZible Campaign with Bristol Myers Squibb and Taye Diggs
Bristol Myers Squibb (NYSE: BMY) has unveiled the Live Your PosSCZible campaign, a nationwide initiative developed in collaboration with the schizophrenia community. The campaign aims to amplify firsthand experiences and…
Live Your PosSCZible Campaign: Bristol Myers Squibb, Taye Diggs, and Schizophrenia Community Unite to Empower Individuals with Schizophrenia
Bristol Myers Squibb (NYSE: BMY) has unveiled the Live Your PosSCZible campaign, a nationwide initiative in collaboration with the schizophrenia community. The campaign aims to amplify personal experiences, offering educational…
AstraZeneca Aims for $80 Billion in Revenue by 2030 with Continued Growth Beyond
Today, AstraZeneca unveiled its ambitious target to achieve $80 billion in Total Revenue by 2030, a significant increase from the $45.8 billion reported in 2023. This expansion will be fueled…
AstraZeneca Announces $1.5 Billion Facility for Antibody Drug Conjugates (ADCs) Manufacturing in Singapore
AstraZeneca to Establish $1.5 Billion Antibody Drug Conjugates (ADCs) Manufacturing Facility in Singapore AstraZeneca plans to build a $1.5 billion manufacturing facility in Singapore, aimed at enhancing the global supply…
FDA Grants Breakthrough Status to Roche’s Inavolisib for Advanced HR+, HER2- Breast Cancer
Roche announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for inavolisib, an investigational oral therapy, in combination with palbociclib (Ibrance®) and fulvestrant. This…
Nurse Leads Clinical Trials for Innovative Cancer Therapies
Several years ago, Melissa Martinez was watching her youngest daughter’s basketball game when a player had a seizure. With no one else knowing how to help, Martinez’s daughter shouted, “My…
Over Half of Crohn’s Patients Achieve Remission with Lilly’s Mirikizumab at One Year
Eli Lilly’s Mirikizumab Shows Promise in Phase 3 Study for Crohn’s Disease In Eli Lilly and Company’s pivotal Phase 3 VIVID-1 study, patients with moderately to severely active Crohn’s disease,…